Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays

We have established a panel of 45 human cancer cell lines (JFCR-45) to explore genes that determine the chemosensitivity of these cell lines to anticancer drugs. JFCR-45 comprises cancer cell lines derived from tumors of three different organs: breast, liver, and stomach. The inclusion of cell lines derived from gastric and hepatic cancers is a major point of novelty of this study. We determined the concentration of 53 anticancer drugs that could induce 50% growth inhibition (GI50) in each cell line. Cluster analysis using the GI50s indicated that JFCR-45 could allow classification of the drugs based on their modes of action, which coincides with previous findings in NCI-60 and JFCR-39. We next investigated gene expression in JFCR-45 and developed an integrated database of chemosensitivity and gene expression in this panel of cell lines. We applied a correlation analysis between gene expression profiles and chemosensitivity profiles, which revealed many candidate genes related to the sensitivity of cancer cells to anticancer drugs. To identify genes that directly determine chemosensitivity, we further tested the ability of these candidate genes to alter sensitivity to anticancer drugs after individually overexpressing each gene in human fibrosarcoma HT1080. We observed that transfection of HT1080 cells with the HSPA1A and JUN genes actually enhanced the sensitivity to mitomycin C, suggesting the direct participation of these genes in mitomycin C sensitivity. These results suggest that an integrated bioinformatical approach using chemosensitivity and gene expression profiling is useful for the identification of genes determining chemosensitivity of cancer cells.

[1]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[2]  K. Fujise,et al.  Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. , 1990, Hepato-gastroenterology.

[3]  K. Kohno,et al.  A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.

[4]  M. Sasaki,et al.  Chemosensitivity of human pancreatic carcinoma cells is enhanced by IkBα super‐repressor , 2003 .

[5]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.

[6]  Seymour S. Cohen.  The mechanisms of lethal action of arabinosyl cytosine (araC) and arabinosyl adenine (araA) , 1977, Cancer.

[7]  R. Morimoto,et al.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.

[8]  K. Abe,et al.  Production of transforming growth factor-alpha in human tumour cell lines. , 1989, British Journal of Cancer.

[9]  Yusuke Nakamura,et al.  Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. , 2002, Cancer research.

[10]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[11]  R. Schimke.  Methotrexate resistance and gene amplification. Mechanisms and implications , 1986, Cancer.

[12]  T. Tsuruo,et al.  Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. , 1999, Cancer research.

[13]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[14]  Yusuke Nakamura,et al.  Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines , 2003, Cancer science.

[15]  H. Sakai,et al.  Telomerase activity is repressed during differentiation along the hepatocytic and biliary epithelial lineages: verification on immortal cell lines from the same origin , 2001, Cell biochemistry and function.

[16]  K Ueda,et al.  Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. , 1990, The Journal of biological chemistry.

[17]  J N Weinstein,et al.  Neural computing in cancer drug development: predicting mechanism of action. , 1992, Science.

[18]  M. Kurosumi,et al.  A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice. , 1996, British Journal of Cancer.

[19]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[20]  Il-Jin Kim,et al.  Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays , 2004, Clinical Cancer Research.

[21]  R. Cuesta,et al.  Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. , 1999, Science.

[22]  今西 幸市.  Production of transforming growth factor-α in human tumor cell lines , 1989 .

[23]  T. Takaoka,et al.  Requirement of serum pretreatment for induction of alkaline phosphatase activity with prednisolone, butyrate, dibutyryl cyclic adenosine monophosphate and NaCl in human liver cells continuously cultured in serum-free medium. , 1988, Cell structure and function.

[24]  K. Higashino,et al.  Production of fibronectin by HUH6 C15 cell line established from a human hepatoblastoma. , 1983, Biochemical and biophysical research communications.

[25]  R. Shiu.  Processing of prolactin by human breast cancer cells in long term tissue culture. , 1980, Journal of Biological Chemistry.

[26]  S. O’Brien,et al.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. , 1978, Cancer research.

[27]  M. Namba,et al.  Establishment and some biological characteristics of human hepatoma cell lines. , 1975, Gan.

[28]  T. Yamori,et al.  Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics , 2003, Cancer Chemotherapy and Pharmacology.

[29]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[31]  A. Tulpule,et al.  Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. , 1986, The Journal of biological chemistry.

[32]  Shinji Tanaka,et al.  Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes , 2004, International journal of cancer.

[33]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[34]  P. Meisel.  Arylamine N-acetyltransferases and drug response. , 2002, Pharmacogenomics.

[35]  Yusuke Nakamura,et al.  Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. , 2002, Molecular cancer therapeutics.

[36]  G. Murray,et al.  Tumour cytochrome P450 and drug activation. , 2002, Current pharmaceutical design.

[37]  D. Gustafson,et al.  Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicumarol. , 1992, Cancer research.

[38]  M. G. Nair,et al.  Synthesis and biological evaluation of poly-gamma-glutamyl derivatives of methotrexate. , 1973, Biochemistry.

[39]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.